Hemab Therapeutics Holdings, Inc. IPO - What You Need to Know

Thinking about the Hemab Therapeutics IPO? Biotech investing is exciting but complex. Here is the breakdown of what you need to know, explained in plain English.

1. What does this company do?

Hemab focuses on blood health. They develop medicines for rare blood-clotting disorders. Their goal is to create treatments that prevent bleeding before it starts, rather than just treating it after an injury.

Their lead drug, sutacimig (HMB-001), is currently being tested for two rare conditions: Glanzmann thrombasthenia and Factor VII deficiency. They use a proprietary platform to build these antibody-based therapies. They also have a second drug, HMB-002, in early development for Von Willebrand Disease. This drug aims to fix the root cause of the disease rather than just replacing missing clotting factors.

2. How do they make money?

They don’t make any money yet. Like most early-stage biotech firms, Hemab is still in the research phase. You are not investing in current profits; you are betting on the potential for their drugs to pass clinical trials and gain government approval.

They lost $63.9 million in 2025, up from $48.7 million in 2024. This loss grew because they are spending more on research and clinical trials. As of late 2025, they had $185 million in cash. They also have $170.9 million in past losses they hope to use to lower future tax bills. However, they warn that an IPO could trigger rules that limit their ability to use these tax breaks.

3. What will they do with the IPO money?

Hemab plans to use the cash to:

• Fund ongoing clinical trials for their lead drug, sutacimig.
• Move their lead drug into "Phase 3" trials—the final, most expensive step before seeking approval to sell the drug.
• Advance research for their second drug, HMB-002.
• Keep labs running and hire more scientific experts.

4. What are the main risks?

Biotech is high-risk. Keep these specific concerns in mind:

• The "All-in" Gamble: The company relies on only two drugs. If these fail to show they are safe or effective, the business has no backup plan.
• Regulatory Hurdles: The FDA might require a larger, more expensive study than planned. This could cause delays and force the company to raise more money.
• Tax & Legal Risks: Operating in both Denmark and the U.S. creates complex tax rules. If tax authorities disagree with how they account for costs between countries, Hemab could face unexpected bills or penalties.
• Dilution: To keep funding research, they may need to sell more shares later. This results in more shares issued, reducing your ownership percentage.

5. Who’s running the company?

Dr. Benny Sørensen serves as President and CEO. The leadership team and scientific advisors have extensive experience at major pharmaceutical companies, specifically in blood disorders.

6. Where will it trade?

Hemab has applied to list on the Nasdaq under the ticker symbol "COAG."

How to make your decision

Before you buy, take these three steps:

1. Read the Prospectus: Search for the "S-1" filing on the SEC’s EDGAR database. It’s long, but it contains the official legal details of every risk mentioned above.
2. Check the Timeline: Look for updates on their clinical trial results. In biotech, a single positive or negative data release can cause the stock price to swing wildly.
3. Assess Your Risk Tolerance: Only invest money you are comfortable losing entirely. Biotech stocks are notoriously volatile, and there is no guarantee that a promising drug will ever reach the market.

Disclaimer: I am an AI, not a financial advisor. Biotech IPOs are extremely volatile. Never invest money you cannot afford to lose, and read the official prospectus on the SEC website before deciding.